Axelrod, Margaret L. http://orcid.org/0000-0003-4713-8798
Meijers, Wouter C.
Screever, Elles M.
Qin, Juan http://orcid.org/0000-0002-0821-6290
Carroll, Mary Grace
Sun, Xiaopeng
Tannous, Elie
Zhang, Yueli
Sugiura, Ayaka http://orcid.org/0000-0001-5326-5019
Taylor, Brandie C.
Hanna, Ann
Zhang, Shaoyi http://orcid.org/0000-0002-8248-9481
Amancherla, Kaushik
Tai, Warren http://orcid.org/0000-0001-9355-7198
Wright, Jordan J. http://orcid.org/0000-0002-2043-0150
Wei, Spencer C.
Opalenik, Susan R.
Toren, Abigail L.
Rathmell, Jeffrey C. http://orcid.org/0000-0002-4106-3396
Ferrell, P. Brent http://orcid.org/0000-0003-1140-9154
Phillips, Elizabeth J. http://orcid.org/0000-0002-7623-3383
Mallal, Simon
Johnson, Douglas B. http://orcid.org/0000-0002-6390-773X
Allison, James P.
Moslehi, Javid J.
Balko, Justin M. http://orcid.org/0000-0002-4263-5974
Article History
Received: 31 January 2022
Accepted: 7 October 2022
First Online: 16 November 2022
Competing interests
: M.L.A. is listed as a co-inventor on a provisional patent application for methods to predict therapeutic outcomes using blood-based gene expression patterns, which is owned by Vanderbilt University Medical Center, and is currently unlicensed. S.C.W. is currently an employee of, and has ownership interest in, Spotlight Therapeutics. S.C.W. has received personal fees from BioEntre and AlphaSights. S.C.W. is an inventor on a patent related to a genetic mouse model of immune checkpoint blockade induced immune-related adverse events (PCT/US2019/050551) pending to the Board of Regents, The University of Texas System and patent applications submitted by Spotlight Therapeutics related to in vivo gene editing. K.A. serves on the Data Safety Monitoring Board for ACI Clinical. J.C.R. is a founder, scientific advisory board member and stockholder of Sitryx Therapeutics, a scientific advisory board member and stockholder of Caribou Biosciences, a member of the scientific advisory board of Nirogy Therapeutics, has consulted for Merck, Pfizer and Mitobridge within the past 3 years, and has received research support from Incyte, Calithera Biosciences and Tempest Therapeutics. P.B.F. receives research support from Incyte. D.B.J. has served on advisory boards or as a consultant for BMS, Catalyst Biopharma, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer and Targovax, has received research funding from BMS and Incyte, and has patents pending for use of MHC-II as a biomarker for ICI response, and abatacept as treatment for irAEs. J.P.A. reports personal fees from Achelois, Adaptive Biotechnologies, Apricity Health, BioAtla, Candel Therapeutics, Codiak BioSciences, Dragonfly Therapeutics, Earli, Enable Medicine, Hummingbird, ImaginAb, Jounce Therapeutics, Lava Therapeutics, Lytix Biopharma, Marker Therapeutics, PBM Capital, Phenomic AI, BioNTech, Polaris Pharma, Time Bioventures, Trained Therapeutics, Two Bear Capital, and Venn Biosciences outside the submitted work. In addition, J.P.A. has a patent for a genetic mouse model of immune-checkpoint-blockade-induced irAEs pending to The University of Texas MD Anderson Cancer Center and has received royalties from intellectual property licensed to BMS and Merck. J.J.M. has served on advisory boards for Bristol Myers Squibb, Takeda, Audentes, Deciphera, Janssen, Immuno-Core, Boston Biomedical, Amgen, Myovant, Kurome Therapeutics, Star Therapeutics, ProtinQure, Pharmacyclics, Pfizer, Mallinckrodt Pharmaceuticals, Silverback Therapeutics, Cytokinetics, and AstraZeneca. J.M.B. receives research support from Genentech/Roche, and Incyte, and is an inventor on provisional patents regarding immunotherapy targets and biomarkers in cancer. No disclosures are reported by the other authors.